作者:Richard A. Glennon、Seoung-Soo Hong、Mikhail Bondarev、Ho Law、Malgorzata Dukat、Suman Rakhit、Patricia Power、Ermei Fan、Diana Kinneau、Rajender Kamboj、Milt Teitler、Katharine Herrick-Davis、Carol Smith
DOI:10.1021/jm950498t
日期:1996.1.1
populations of receptors. Examination of a series of 5-(alkyloxy)tryptamine derivatives demonstrated that compounds with unbranched alkyl groups of up to eight carbon atoms bind with high affinity at human 5-HT1D beta receptors (Ki < 5 nM) but demonstrate less than 50-fold selectivity relative to 5-HT1A receptors. Alkyl groups longer than eight carbon atoms impart reduced affinity for 5-HT1A receptors whereas
在人类中,5-HT1D血清素受体代表末端自身受体,并且有一些证据表明5-HT1D配体可用于治疗偏头痛。最广泛使用的5-HT1D激动剂是舒马普坦。然而,据报道该试剂对5-HT1D的选择性相对于5-HT1A受体几乎没有。为了鉴定具有增强的5-HT1D相对于5-HT1A选择性的新型5-羟色胺能药物,我们尝试利用与这两个受体的5-HT结合位点的5-位相关的体积耐受性区域中的可能差异。对一系列5-(烷氧基)色胺的衍生物的研究表明,具有多达8个碳原子的直链烷基的化合物以高亲和力与人5-HT1Dβ受体结合(Ki < 5 nM),但相对于5-HT1A受体,选择性不足50倍。长于八个碳原子的烷基会降低对5-HT1A受体的亲和力,而长于九个碳原子的烷基会导致对5-HT1Dβ受体的亲和力降低的化合物。5-(壬氧基)色胺(10)代表具有最佳5-HT1Dβ亲和力(Ki = 1 nM)和选择性(> 300倍)的化合物。烷基链分支成5-[((7